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ANTIMICROBIAL USE AND THE INFLUENCE OF
INADEQUATE EMPIRIC ANTIMICROBIAL THERAPY ON
THE OUTCOMES OF NOSOCOMIAL BLOODSTREAM
INFECTIONS IN A NEONATAL INTENSIVE CARE UNIT
Anucha Apisarnthanarak, MD; Galit Holzmann-Pazgal, MD; Aaron Hamvas, MD; Margaret A. Olsen, PhD, MPH;
Victoria J. Fraser, MD
Inadequate antimicrobial therapy for infections has
been defined in multiple ways, including (1) microbiolog-
ical documentation of an infection that was not being
effectively treated at the time of its identification; (2)
absence of antimicrobial agents directed against a specif-
ic class of microorganisms; and (3) administration of an
antimicrobial agent to which the microorganism responsi-
ble for the infection was resistant.1,2 In addition, the
absence of antimicrobial therapy for a confirmed infection
is also considered to represent inadequate antimicrobial
therapy.1
Several studies have demonstrated a correlation
between adequate empiric antimicrobial therapy for
bloodstream infection (BSI) and low mortality rates in
adult patients.3-6 Identified risk factors for the administra-
tion of inadequate empiric antimicrobial therapy in
patients with BSI include prior administration of antibi-
otics, presence of central venous catheters, infection due
to Staphylococcus aureus, and infections due to antibiotic-
resistant pathogens (Candida species, methicillin-
resistant, vancomycin-resistant Enterococcus, and coagu-
lase-negative staphylococci).6-8 However, there are no
data on the relationship between the adequacy of empiric
antimicrobial therapy and the outcomes of nosocomial
BSIs in neonatal patients. Because neonates and adults
have different anatomies, physiologies, and underlying
diseases, as well as patterns of antibiotic use and antimi-
crobial resistance, specific studies of the outcomes of
inadequate empiric antimicrobial therapy in neonates are
needed. 
We performed a prospective cohort study to deter-
mine the rates and microbiology of nosocomial BSI,
patterns of antibiotic use, and relationship between the ade-
quacy of prescribed empiric antimicrobial therapy for noso-
comial BSI and clinical outcomes in a neonatal intensive
care unit (NICU). 
Dr. Apisarnthanarak is from the Division of Infectious Diseases, Faculty of Medicine, Thammasart University Hospital, Pratumthani,
Thailand. Drs. Holzmann-Pazgal, Olsen, and Fraser are from the Division of Infectious Diseases, Departments of Pediatric and Internal Medicine,
and Dr. Hamvas is from the Division of Newborn Medicine, St. Louis Children’s Hospital, BJC Health Care and Washington University School of
Medicine, St. Louis, Missouri.
Address reprint requests to Victoria J. Fraser, MD, Washington University School of Medicine, Campus Box 8051, 660 South Euclid Ave., St.
Louis, MO 63110.
Supported by a grant from the National Foundation for Infectious Diseases (Dr. Holzmann-Pazgal) and in part by the Centers for Disease
Control and Prevention Cooperative Agreement no. UR8/CCU715087 (Dr. Fraser). 
The authors thank J. Russell Little, MD, and Hillary B. Babcock, MD, for critical review of this manuscript.
OBJECTIVE: To evaluate antimicrobial use and the influ-
ence of inadequate empiric antimicrobial therapy on the out-
comes of nosocomial bloodstream infections (BSIs).
DESIGN: Prospective cohort study with nested case–con-
trol analysis.
SETTING: Neonatal intensive care unit (NICU). 
METHODS: All patients weighing 2,000 g or less were
enrolled. Data collection included risk factors for nosocomial
BSI, admission severity of illness, microbiology, antimicrobial
therapy, and outcomes. Inadequate empiric antimicrobial therapy
was defined as the use of antibiotics for more than 48 hours after
the day that blood cultures were performed that did not cover the
microorganisms causing the bacteremia or administration of
antibiotics that failed to cover resistant microorganisms. 
RESULTS: Two hundred twenty-nine patients were
enrolled. Forty-five developed nosocomial BSIs. The BSI rates
were 11.2, 2.8, and 0 per 1,000 catheter-days for patients weigh-
ing 1,000 g or less, between 1,001 and 1,500 g, and between 1,501
and 2,000 g, respectively. After adjustment for severity of illness,
the mortality in patients with nosocomial BSI receiving inade-
quate empiric antimicrobial therapy was higher than in those
receiving adequate therapy (adjusted odds ratio [AOR], 5.3; 95%
confidence interval [CI95], 1.2–23.2). By multivariate analysis,
nosocomial BSI attributed to Candida species (AOR, 6.3; CI95,
1.4–28.0) and invasive procedure prior to onset of BSI (AOR, 6.4;
CI95, 1.0–39.0) were associated with administration of inadequate
empiric antimicrobial therapy. 
CONCLUSIONS: Administration of inadequate empiric
antimicrobial therapy among NICU patients with nosocomial BSI
was associated with higher mortality. Additional studies on the
role of inadequate empiric antimicrobial therapy and the out-
comes of BSIs among NICU patients are needed (Infect Control
Hosp Epidemiol 2004;25:735-741).
ABSTRACT
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METHODS
Setting and Empiric Antimicrobial Therapy
St. Louis Children’s Hospital is a 235-bed, tertiary-
care center affiliated with Washington University School of
Medicine. St. Louis Children’s Hospital has a level-III, 52-
bed NICU with 700 to 750 admissions per year and an aver-
age census of 50 patients. The NICU staff includes 3
neonatologists, 2 newborn medicine fellows, and 5 pedi-
atric house staff and nurse practitioners. The estimated
patient-to-nurse ratio is 2 to 1. In this NICU, ampicillin and
aminoglycosides are generally used for empiric treatment
of patients with clinically suspected sepsis within the first
7 days of life. Vancomycin and aminoglycosides are admin-
istered to patients with clinically suspected sepsis after the
first 7 days of life. For patients who were previously infect-
ed with specific pathogens, empiric antimicrobial therapy
was modified to cover for those pathogens in addition to
the standard spectrum of antimicrobial coverage within or
after the first 7 days of life. 
Patients
From October 1, 2000, to July 31, 2001, all patients
with a birth weight of 2,000 g or less admitted to the NICU
for longer than 48 hours were included in the study.
Patients transferred to the NICU from an outside hospital
were included as long as their birth weight was 2,000 g or
less, even if their weight on admission to the NICU was
more than 2,000 g. The development of nosocomial infec-
tion was monitored from the day of admission until dis-
charge from the NICU. If the patients were discharged to
another St. Louis Children’s Hospital location or to
the nursery of an af filiated university hospital
(Barnes–Jewish Hospital), they were observed for an
additional 48 hours. Approval was obtained from the insti-
tutional review boards of Washington University and St.
Louis Children’s Hospital prior to the initiation of the
study. 
Study Design and Data Collection
A prospective cohort study design was used with a
subsequent nested case–control study. Patients with noso-
comial BSIs were classified according to the adequacy of
their empiric antimicrobial therapy, with NICU mortality
as the main outcome variable. Another outcome mea-
sured was the length of stay in the NICU. For the purpos-
es of this investigation, inadequate empiric antimicrobial
therapy for nosocomial BSI was defined as the use of
antibiotics for longer than 48 hours following the day that
the blood cultures were performed that did not have effi-
cacy against the identified microorganisms. Inadequate
antimicrobial therapy included the absence of antimicro-
bial agents directed at the specific class of recovered
microorganisms or administration of ineffective antimi-
crobial agents due to the microorganisms’ drug resis-
tance patterns. One of the authors (AA), an infectious dis-
eases fellow, reviewed medical records to confirm that
these neonates had received inadequate empiric antimi-
crobial therapy for longer than 48 hours.
Medical records, including charts, daily flow
sheets, and laboratory and radiographic reports, were
prospectively reviewed by one of the investigators (GH-
P). For all study patients, the following characteristics
were prospectively recorded: gender, race, estimated 
gestational age, underlying diseases, administration of
therapeutic antibiotics, placement of central venous and
arterial catheters, ventilator use, invasive procedures,
microbiology data (microorganisms and their susceptibil-
ity results), length of stay in the NICU, concurrent noso-
comial infections, and mortality. Severity of illness on
admission was calculated using the Score for Neonatal
Acute Physiology–Perinatal Extension (SNAP–PE)
derived from the first 24 hours of NICU admission accord-
ing to the method of Richardson et al.9,10 Invasive proce-
dures included patent ductus arteriosus ligation, laparoto-
my, and chest tube placement. Specific processes of 
medical care that were examined included the adminis-
tration of corticosteroids, antacids, and histamine type-2
blockers.
Definitions
A nosocomial infection was defined as an infection
not present or incubating at the time of NICU admission,
with onset after 48 hours of NICU stay.11 Isolation of a
high-grade pathogen (eg, Pseudomonas aeruginosa or
Staphylococcus aureus) in one or more blood culture speci-
mens was considered definitive evidence of bacteremia. In
our NICU, only a single blood culture was routinely per-
formed for neonates with intravenous catheters. Therefore,
we developed more stringent criteria for the isolation of
organisms commonly associated with skin contamination
from a single positive blood culture, such as coagulase-neg-
ative Staphylococcus. This criterion for primary bacteremia
required a diagnosis of sepsis by an attending physician in
the NICU if only one positive blood culture was performed
prior to the initiation of antibiotics. Secondary BSI was
defined as bacteremia due to the presence of a localized
infection at another site that occurred within 1 week before
the development of the bacteremia or simultaneously.
A bacteremic episode was included as a new
episode if a new microorganism was isolated from a blood
culture or when the original microorganism was recov-
ered again more than 2 weeks after the first episode with
negative blood cultures in the interim. Empiric therapy
was considered to be present when antimicrobials were
prescribed for fever or other systemic signs of infection
such as hypothermia or leukocytosis before identification
of the causative microorganisms. Early-onset bacteremia
was defined as bacteremia occurring within the first 7
days of life, and late-onset bacteremia was defined as bac-
teremia occurring after 7 days of life. Crude mortality
related to nosocomial BSI was defined as patient death
occurring within 7 days of the bacteremia and during
treatment for nosocomial BSI. 
To identify factors for BSI-related mortality, risk fac-
tors were evaluated from the time of NICU admission
until the occurrence of the last episode of nosocomial BSI.
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To identify risk factors for receipt of inadequate empiric
antimicrobial therapy, risk factors were evaluated from
admission until the first episode of bacteremia for patients
who received inadequate empiric antimicrobial treatment,
and from admission until the last episode of bacteremia
for patients who received adequate empiric antimicrobial
treatment.
Statistical Analysis
A nested case–control method was used to analyze
risk factors and outcomes of inadequate antimicrobial ther-
apy. SPSS software (version 10.0; SPSS, Inc., Chicago, IL)
was used to analyze the data. Proportions were compared
using chi-square or Fisher’s exact test as appropriate.
Continuous variables were compared by use of the
Mann–Whitney U test. All P values were two-tailed. A P
value of .05 or less was considered statistically significant.
Adjusted odds ratios (ORs) and 95% confidence intervals
(CI95) were computed for categorical variables. Multi-
variate logistic regression was performed to assess the pre-
dictive association of inadequate empiric antimicrobial
therapy with crude mortality. To identify independent risk
factors for inadequate empiric antimicrobial therapy, back-
ward stepwise logistic regression was performed. Variables
that were present in more than 10% of the population with a
P value of less than .20 or that had a priori clinical signifi-
cance were entered into the models. Significant variables
that were thought to co-vary were grouped, and only one
variable from each group was chosen for entry into the
model. The final model was chosen on the basis of biologi-
cal plausibility and by selecting the logistic regression
model with the lowest -2 log-likelihood function.
TABLE 1
PATIENT CHARACTERISTICS
Patients in Patients Who Patients Who
Entire Developed Did Not Develop
Cohort BSI BSI
Characteristic (n = 229) (n = 45) (n = 184) P*
Demographic
Female 114 (50%) 24 (53%) 90 (49%) .59
White 113 (49%) 20 (44%) 93 (51%) .46
Median SNAP–PE score (range)† 16 (2–70) 40 (6–70) 14 (2–70) < .001
Birth weight, g
< 1,000 85 (37%) 31 (69%) 54 (29%) < .001
1,000 to 2,000 144 (63%) 14 (31%) 130 (71%) < .001
Median estimated gestational age, wk (range)† 29 (22–39) 26 (22–34) 29 (22–39) < .001
Invasive procedure‡
Patent ductus arteriosus ligation 10 (4%) 5 (11%) 5 (3%) .02
Chest tube placement 7 (3%) 2 (4%) 5 (3%) .54
Laparotomy 4 (2%) 2 (4%) 2 (1%) .12
Underlying disease
Congenital heart diseases§ 28 (12%) 10 (22%) 18 (10%) .02
Patent ductus arteriosus 73 (32%) 21 (47%) 52 (28%) < .001
Bronchopulmonary dysplasia 63 (28%) 30 (67%) 33 (18%) < .001
Respiratory distress syndrome 200 (87%) 34 (76%) 166 (90%) .008
Medication
Dexamethasone 74 (32%) 37 (82%) 37 (20%) < .001
Surfactant 196 (86%) 34 (76%) 162 (88%) .03
Histamine type-2 receptor blockers 64 (28%) 27 (60%) 37 (20%) < .001
Intravenous gamma globulin 18 (8%) 10 (22%) 8 (4%) < .001
Indomethacin 48 (21%) 24 (53%) 24 (13%) < .001
Outcome
Total median NICU stay, d (range) 30 (3–361) 96 (4–312) 30 (3–361) < .001
Death 24 (11%) 12 (27%) 12 (7%) < .001
BSI = bloodstream infection; SNAP–PE = Score for Neonatal Acute Physiology–Perinatal Extension; NICU = neonatal intensive care unit.
*Analyzed by chi-square or Fisher’s exact test, as appropriate, unless otherwise noted.
†Analyzed by Mann–Whitney test.
‡All invasive procedures were performed prior to the first episode of bacteremia.
§Includes any anatomy other than normal four-chamber heart with left ventricle and excludes patent foramen ovalae and patent ductus arteriosus.
All medications were administered prior to the first episode of bacteremia.
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RESULTS
Cohort Characteristics
Forty-five (20%) of 229 patients who were enrolled in
the study developed nosocomial BSI. Two (4%) of the
patients were transferred to our institution from outside
hospitals prior to the onset of BSI on their second day of
life. The median birth weight was 740 g (range, 420 to 1,705
g) and the median gestational age was 26 weeks (range, 22
to 34 weeks). Thirty-four (76%) of the patients had primary
BSI only, 5 patients (11%) had secondary BSI only, and 6
patients (13%) had both primary and secondary BSI.
Sources of secondary BSI were the respiratory tract (6 of
11; 55%) and urinary tract (5 of 11; 45%). The median rates
of BSI were 11.2, 2.8, and 0 per 1,000 catheter-days for
patients weighing 1,000 g or less, 1,001 to 1,500 g, and 1,501
to 2,000 g, respectively. The median duration from admis-
sion to the first onset of nosocomial BSI was 15 days
(range, 2 to 52 days). Twenty-three (51%) of the 45 patients
had more than one BSI episode (range, 2 to 5 episodes).
Nine patients had invasive procedures performed prior to
the first onset of BSI. The median duration from invasive
procedure to the first onset of nosocomial BSI was 18 days
(range, 5 to 53 days). Demographics and clinical character-
istics for the cohort of patients are summarized and com-
pared in Table 1. 
There were 90 bacteremic episodes, which occurred
in 45 patients. Thirteen episodes (14%) occurred within
the first 7 days of life, and 77 (86%) occurred after 7 days
of life. Coagulase-negative Staphylococcus (39 of 90; 43%),
Candida species (13 of 90; 14%), and Escherichia coli (9 of
90; 10%) were the most common microorganisms isolated
from the blood cultures. The distribution of microorgan-
isms according to the time of onset is presented in Table
2. Fifteen patients had nosocomial infections other than
BSIs. Of these patients, 11 developed pneumonia or uri-
nary tract infection due to Pseudomonas species (n = 6),
Enterobacter species (n = 3), or Escherichia coli (n = 2),
whereas 4 patients developed pneumonia or urinary tract
infection due to Pseudomonas species (n = 2), Enterobacter
species (n = 1), or Escherichia coli (n = 1) together with
candidal urinary tract infection (n = 4). Eleven (73%) of
these 15 patients developed secondary BSIs, including 2
(50%) of 4 patients who had candidemia in association
with urinary tract infections. The median duration from
prior nosocomial infection to onset of secondary BSI was
5 days (range, 1 to 7 days). 
Treatment Given and the Adequacy of Therapy
The empiric antimicrobial regimens used in the 90
episodes of BSI are listed in Table 3. The median duration
of antimicrobial therapy for each bacteremic episode was
14 days (range, 4 to 28 days). BSI caused by coagulase-neg-
ative Staphylococcus occurred in 18 (40%) of the 45 patients.
There was no difference in characteristics or crude mor-
tality among patients who developed BSI due to coagulase-
negative Staphylococcus versus non–coagulase-negative
microorganisms (P = .56), or among patients who devel-
oped early-onset versus late-onset nosocomial BSI (P > .99).
Twenty-one (47%) of the patients had 21 episodes of
inadequate empiric antimicrobial therapy. Each patient
had one episode of inadequate empiric antimicrobial ther-
TABLE 2
MICROORGANISMS ASSOCIATED WITH THE BLOODSTREAM
INFECTIONS
Total BSI Within BSI
No. of the First After
BSI 7 Days 7 Days
Episodes of Life of Life
Pathogen (n = 90) (n = 13) (n = 77)
Coagulase-negative 39 (43%) 10 (77%) 29 (38%)
Staphylococcus
Staphylococcus aureus 7 (8%) 1 (8%) 6 (8%)
Enterococcus species 3 (3%) 0 (0%) 3 (4%)
Alpha-hemolytic 5 (6%) 0 (0%) 5 (7%)
Streptococcus
Escherichia coli 9 (10%) 2 (15%) 7 (9%)
Klebsiella pneumoniae 5 (6%) 0 (0%) 5 (7%)
Enterobacter species 5 (6%) 0 (0%) 5 (7%)
Pseudomonas species 4 (4%) 0 (0%) 4 (5%)
Candida species 13 (14%) 0 (0%) 13 (17%)
BSI = bloodstream infection.
TABLE 3
EMPIRIC ANTIBIOTIC REGIMENS FOR THE BLOODSTREAM
INFECTIONS
Regimen Frequency (%)*
Early-onset bacteremia (n = 13 episodes)†,‡
Ampicillin and aminoglycosides 13 (100)
Late-onset bacteremia (n = 77 episodes)§,
Vancomycin and aminoglycosides 62 (81)
Vancomycin and ceftazidime¶ 6 (8)
Vancomycin and extended-spectrum penicillin# 3 (4)
Vancomycin and ceftriaxone** 2 (3)
Vancomycin, ceftazidime, and fluconazole†† 2 (3)
Vancomycin, ceftriaxone, and fluconazole‡‡ 1 (1)
Vancomycin, extended-spectrum penicillin, 1 (1)
and fluconazole§§
*Total bacteremic episodes.
†Bloodstream infection that occurred within the first 7 days of life.
‡Ampicillin was changed to vancomycin in 8 episodes of early-onset bacteremia to cover for
coagulase-negative Staphylococcus bacteremia.
§Bloodstream infection that occurred after the first 7 days of life.
Amphotericin B was added on 7 episodes of late-onset bacteremia to cover for candidemia.
¶These patients had evidence of Pseudomonas species infections prior to onset of bacteremia.
#These patients had evidence of Enterobacter species infections prior to onset of bacteremia.
**These patients had evidence of Escherichia coli infections prior to onset of bacteremia.
††These patients had evidence of Pseudomonas species and Candida infections prior to onset of
bacteremia.
‡‡These patients had evidence of Escherichia coli and Candida species infections prior to onset
of bacteremia.
§§These patients had evidence of Enterobacter species and Candida species infections prior to
onset of bacteremia.  
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apy for nosocomial BSI. The reasons for inadequate
empiric antimicrobial treatment and the microorganisms
associated with it are listed in Table 4. Twelve patients
had delayed receipt of adequate antimicrobial therapy; the
median delay was 2 days (range, 2 to 3 days). There was
no difference in crude mortality between patients who
received delayed versus adequate empiric antimicrobial
treatment (OR, 2.6; 5 [42%] of 12 vs 7 [21%] of 33; P = .25).
Effect of Inadequate Empiric Antimicrobial
Therapy
Twelve patients with nosocomial BSI died. Four
(33%) of the 12 deaths occurred during therapy for early-
onset bacteremia, and 8 (67%) of the deaths occurred dur-
ing therapy for late-onset bacteremia. Nine (75%) of the 12
patients had received inadequate empiric antimicrobial
therapy. The reasons for inadequate empiric antimicrobial
therapy in these patients were absence of antimicrobial
agents directed at a specific class of recovered microor-
ganisms on the day that blood cultures were performed (6
of 9; 67%) and institution of antimicrobial treatment that
failed to cover antibiotic-resistant microorganisms (3 of 9;
33%). There were 11 microorganisms associated with
death in 9 patients (coagulase-negative Staphylococcus
[n = 4], S. aureus [n = 2], Escherichia coli [n = 2],
Enterobacter species [n = 1], and Candida species [n = 2]).
Two patients had two microorganisms that grew from
blood cultures (coagulase-negative Staphylococcus [n = 2]
together with Escherichia coli [n = 2]). All deaths in
patients with coagulase-negative Staphylococcus BSI
occurred during the early-onset bacteremia. There was no
difference in the crude mortality among patients who
developed candidemia versus those who did not (OR, 1.3;
4 [31%] of 13 vs 8 [25%] of 32; P = .98]. The median dura-
tion from the last BSI episode until death was 4 days
(range, 1 to 7 days). 
The clinical characteristics among survivors versus
nonsurvivors of BSI in the NICU are listed in Table 5. On
univariate analysis, inadequate empiric antimicrobial
therapy was the only factor associated with mortality
(OR, 5.25; 9 [75%] of 12 vs 12 [36%] of 33; P = .02).
Because severity of illness was considered to be a poten-
tially important confounder, logistic regression was used
to estimate the effect of inadequate antimicrobial therapy
on mortality and to adjust for severity of illness.
TABLE 4
REASONS FOR INADEQUATE ANTIMICROBIAL TREATMENT
Reason Frequency (%)*
Early-onset bacteremia (n = 10 episodes)†
Absence of antimicrobial agents directed 
at a specific class of microorganisms
Coagulase-negative Staphylococcus species 10 (100)    
Late-onset bacteremia (n = 11 episodes)‡
Absence of antimicrobial agents directed 
at a specific class of microorganisms
Candida species 7 (64)
Administration of antibiotic to resistant 
microorganisms
Pseudomonas species§ 2 (18)
Enterobacter species§ 1 (9)
Escherichia coli§ 1 (9)
*Total episodes of inadequate empiric antimicrobial treatment.
†Bloodstream infection that occurred within the first 7 days of life.
‡Bloodstream infection that occurred after the first 7 days of life.
§This organism was resistant to third-generation cephalosporins, extended-spectrum penicillin,
or both.
TABLE 5
CHARACTERISTICS AMONG NONSURVIVORS VERSUS SURVIVORS OF
BLOODSTREAM INFECTION IN THE NEONATAL INTENSIVE CARE
UNIT
Nonsurvivors Survivors
Characteristic* (n = 12) (n = 33) P†
Demographic
Female 8 (67%) 16 (48%) .28
White 5 (42%) 15 (45%) 1.00
Median SNAP–PE score 46 (10–70) 33 (6–41) .44
(range)‡
Birth weight, g
 1,000 8 (67%) 23 (70%) 1.00
1,001 to 2,000 4 (33%) 10 (30%) 1.00
Median estimated gestational 26 (23–33) 26 (22–34) .83
age, wk (range)‡
Underlying disease
Congenital heart disease§ 3 (25%) 7 (21%) 1.00
Patent ductus arteriosus 6 (50%) 15 (45%) .79
Bronchopulmonary dysplasia 8 (67%) 22 (67%) 1.00
Respiratory distress syndrome 10 (83%) 24 (73%) .69
Invasive procedure 4 (33%) 5 (15%) .21
Medication¶
Dexamethasone 10 (83%) 27 (82%) .69
Surfactant 10 (83%) 24 (73%) .69
Histamine type-2 receptor 7 (58%) 20 (61%) .71
antagonist
Intravenous gamma globulin 3 (25%) 7 (21%) 1.00
Indomethacin 6 (50%) 18 (55%) .78
Episodes of inadequate anti- 9 (75%) 12 (36%) .02
microbial therapy
Outcome
Median NICU stay, 138 (4–240) 99 (15–312) .22
d (range)‡
SNAP–PE = Score for Neonatal Acute Physiology–Perinatal Extension; NICU = neonatal inten-
sive care unit.
*All risk factors were evaluated from the time of NICU admission until the occurrence of the
last episode of bloodstream infection.
†Analyzed by chi-square or Fisher’s exact test, as appropriate.
‡Analyzed by Mann-Whitney test.
§Includes any anatomy other than normal four-chamber heart with left ventricle and excludes
patent foramen ovalae and patent ductus arteriosus.
All invasive procedures were performed prior to the last episode of bacteremia.
¶All medications were administered prior to the last episode of bloodstream infection.
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Inadequate empiric antimicrobial therapy remained sig-
nificant after adjustment for severity of illness (adjusted
OR, 5.3; CI95, 1.2 to 23.2; P = .04). We also examined the
potentially confounding effects of length of stay in the
NICU prior to the onset of BSI and gestational age; they
did not materially affect the estimate of the effect (ORs). 
Risk Factors for Inadequate Antimicrobial
Therapy
The only significant risk factor associated with the
administration of inadequate empiric antimicrobial treat-
ment on univariate analysis was nosocomial BSI attrib-
uted to Candida species (OR, 6.3; CI95, 1.4 to 28.0; P = .02)
(Table 6). Multivariate logistic regression was used to
identify independent risk factors for inadequate empiric
antimicrobial treatment. The final model included can-
didemia (adjusted OR, 7.1; CI95, 1.5 to 33.7; P = .01) and
invasive procedure prior to the onset of BSI (adjusted OR,
6.4; CI95, 1.0 to 39.0; P = .04). On univariate analysis, prior
BSI was the only significant risk factor associated with
candidemia (OR, 8.0; CI95, 1.6 to 45.2; P = .003). Due to the
limitation of the sample size, logistic regression was not
performed for candidemia as an outcome. 
DISCUSSION
Our study is the first to describe antibiotic use,
antimicrobial resistance, and the influence of inadequate
empiric antimicrobial therapy on outcomes of nosocomial
BSIs in patients in the NICU. This study demonstrated
that critically ill patients with BSI in the NICU who
received inadequate empiric antimicrobial therapy were
significantly more likely to die during their hospitalization
compared with those receiving adequate empiric antimi-
crobial therapy. We also identified BSI caused by Candida
species and invasive procedures prior to the onset of BSI
as potential risk factors for the administration of inade-
quate empiric antimicrobial therapy. 
According to the data of the National Nosocomial
Infections Surveillance System, median BSI rates are 12,
7.3, and 4.7 per 1,000 catheter-days for neonates weighing
1,000 g or less, 1,001 to 1,500 g, and 1,501 to 2,500 g,
respectively.12 In the literature, coagulase-negative
Staphylococcus is the predominant organism in all studies,
whereas the proportions of other microorganisms vary
greatly in each study.13-19 In our study, the median rates of
nosocomial BSI were similar to those of the National
Nosocomial Infections Surveillance System for patients
weighing 1,000 g or less, between the 10th and 25th per-
centile for patients weighing 1,001 to 1,500 g, and at the
0th percentile for patients weighing 1,501 to 2,500 g. The
distribution of the microorganisms in our study was simi-
lar to that reported by Beck-Sague et al.14
Several studies of adults have shown a significant
reduction in mortality associated with adequate empiric
antibiotic treatment,4,20-23 whereas others failed to identify
this association.24-27 The varying outcomes in these stud-
ies might be due to the definitions used for adequacy of
empiric antimicrobial therapy. Our results confirmed the
association of inadequate antimicrobial therapy with
adverse outcomes.
Risk factors for the administration of inadequate
empiric antimicrobial therapy to adult patients with BSI
are well recognized,6-8 but little has been published
regarding neonatal patients. The role of invasive proce-
dures prior to the onset of bacteremia is not entirely clear,
although this factor may reflect greater severity of illness,
which may predispose to colonization and infection with
antibiotic-resistant organisms. We confirmed candidemia
as a risk factor associated with inadequate empiric antimi-
crobial therapy, as has been consistently shown in previ-
ous adult studies.6-8 Although there are no current recom-
mendations for empiric antifungal therapy in neonates,
there may be specific groups of patients identified in the
future who would benefit from such an approach.28
There are several limitations to this study. Because
it was conducted at a tertiary-care hospital that uses
guidelines for empiric antimicrobial therapy for suspected
sepsis, our results may not be applicable to other hospi-
tals with lower rates of BSI caused by Candida species or
hospitals that do not have guidelines for empiric antimi-
crobial therapy. Our sample size was not large enough to
exclude the possibility of characteristics unique to
patients depending on the causative agents of bacteremias
or to identify other risk factors associated with inadequate
empiric antimicrobial therapy and outcomes. In addition,
TABLE 6
RISK FACTORS FOR INADEQUATE EMPIRIC ANTIMICROBIAL
THERAPY FOR BLOODSTREAM INFECTION AMONG PATIENTS IN THE
NEONATAL INTENSIVE CARE UNIT ON UNIVARIATE ANALYSIS
Inadequate Adequate
Antimicrobial Antimicrobial
Dichotomous Therapy Therapy
Variable* (n = 21)† (n = 24) P‡
Candidemia 10 (48%) 3 (13%) .02
Estimated gestational 5 (24%) 5 (21%) 1.00
age < 24 wk§
Invasive procedure 7 (33%) 2 (8%) .06
SNAP–PE score > 32§ 14 (67%) 12 (50%) .36
Prior BSI 5 (24%) 9 (38%) .35
Prior antibiotic use 11 (52%) 14 (58%) .70
Prior nosocomial 6 (29%) 5 (21%) .55
infections excluding BSI
Antibiotics  > 18 d§ 4 (19%) 5 (21%) 1.0
NICU stay prior 7 (33%) 6 (25%) .74
to BSI > 75 d§
SNAP–PE = Score for Neonatal Acute Physiology–Perinatal Extension; BSI = bloodstream infec-
tion; NICU = neonatal intensive care unit.
*All risk factors were abstracted prior to the first episode of inadequate empiric antimicrobial
therapy for BSI in patients who received inadequate empiric antimicrobial treatment vs the last
episode of BSI in patients who received adequate empiric antimicrobial treatment.
†Twenty-one patients each had one episode of inadequate empiric antimicrobial treatment.
‡Analyzed by chi-square or Fisher’s exact test, as appropriate, unless otherwise noted.
§The number represents the 75th percentile.
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the large confidence intervals of the ORs make it difficult
to estimate the true effect size between risk factors and
outcomes. Because all of our patients had a single blood
culture performed from a central venous catheter, it was
difficult to ascertain whether coagulase-negative staphy-
lococci episodes represented true bacteremias. Most of
the patients in our NICU developed late-onset BSI (medi-
an onset, 15 days); thus, it is likely that the SNAP–PE
score on admission was not as informative as a SNAP–PE
score immediately before the onset of BSI. Finally, the
observational nature of this investigation did not allow us
to detect an absolute causal relationship between the
administration of inadequate empiric antimicrobial treat-
ment and specific clinical outcomes including hospital
mortality.
Our data suggest that inadequate empiric antimi-
crobial therapy was associated with adverse outcomes in
patients in the NICU. Physicians in the NICU should be
able to balance the need to provide adequate empiric
antimicrobial therapy with the risk of selecting for resis-
tant microorganisms. Studies on the role of inadequate
antimicrobial therapy and outcomes in patients in the
NICU are needed.
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